References
- Adrade da Mata Rezende CM, Von Bulow MV, Gottlieb OR, Lamego Vieira Pinho S, Da Rocha AI. 1971. The 2-pyrones of Aniba species. Phytochemistry. 10:3167–3171.
- Bilia AR, Gallon S, Vincieri FF. 2002. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 70:2581–2597.10.1016/S0024-3205(02)01555-2
- Dharmaratne HR, Dhammika Nanayakkaraa NP, Khana IA. 2002. Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochemistry. 59:429–433.
- Gigliarelli G, Pagiotti R, Persia D, Marcotullio MC. 2017. Optimisation of a Naviglio-assisted extraction followed by determination of piperine content in Piper longum extracts. Nat Prod Res. 31:214–217.10.1080/14786419.2016.1217209
- Heilmann J, Wasescha MR, Schmidt TJ. 2001. The influence of glutathione and cysteine levels on the cytotoxicity of helenanolide type sesquiterpene lactones against KB cells. Bioorg Med Chem. 9:2189–2194.10.1016/S0968-0896(01)00131-6
- Masanori K, Yooko Y, Seigo F, Akira U, Tadataka N, Toshio M. 1982. Chemical studies on the constituents of Polygonum nodosum. Chem Pharm Bull. 30:1602–1606.
- Olsen LR, Grillo MP, Skonberg C. 2011. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol. 24:992–1002.10.1021/tx100412m
- Parmar VS, Jain SC, Bisht KS, Jain R, Taneja P, Jha A, Tyagi OD, Prasad AK, Wengel J, Olsen CE, Boll PM. 1997. Phytochemistry of the genus Piper. Phytochemistry. 46:597–673.10.1016/S0031-9422(97)00328-2
- Pittler MH, Ernst E. 2000. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol. 20:84–89.10.1097/00004714-200002000-00014
- Sagawa T, Takaishi Y, Fujimoto Y, Duque C, Osorio C, Ramos F, Garzon C, Sato M, Okamoto M, Oshikawa T, Ahmed SU. 2005. Cyclobutane dimers from the Colombian medicinal plant achyrocline bogotensis. J Nat Prod. 68:502–505.10.1021/np040187y
- Sarris J, Kavanagh DJ. 2009. Kava and St. John’s wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med. 15:827–836.10.1089/acm.2009.0066
- Shi YN, Yang L, Zhao JH, Shi YM, Qu Y, Zhu HT, Wang D, Yang CR, Li XC, Xu M, Zhang YJ. 2015. Chemical constituents from Piper wallichii. Nat Prod Res. 29:1372–1375.10.1080/14786419.2014.998217
- Singh YN, Blumenthal M. 1997. Kava: an overview. Distribution, mythology, culture, chemistry and pharmacology of the South Pacific’s most revered herb. Herbalgram. 39:33–56.
- Singh YN, Singh NN. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 16:731–743.10.2165/00023210-200216110-00002
- Teschke R. 2010a. Kava hepatotoxicity: a clinical review. Ann Hepatol. 9:251–265.
- Teschke R. 2010b. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 30:1270–1279.10.1111/j.1478-3231.2010.02308.x
- Teschke R, Lebot V. 2011. Proposal for a kava quality standardization code. Food Chem Toxicol. 49:2503–2516.10.1016/j.fct.2011.06.075
- Teschke R, Schwarzenboeck A, Hennermann KH. 2008. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 20:1182–1193.10.1097/MEG.0b013e3283036768
- Teschke R, Qiu SX, Xuan TD, Lebot V. 2011. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res. 25:1262–1274.
- Teschke R, Sarris J, Lebot V. 2011. Contaminant hepatotoxins as culprits for hepatotoxicity–fact or fiction? Phytother Res. 27:472–474.
- Tu Y, Zhong Y, Du HJ, Luo W, Wen YY, Li Q, Zhu C, Li Y. 2016. Anticholinesterases and antioxidant alkamides from Piper nigrum fruits. Nat Prod Res. 30:1945–1949.10.1080/14786419.2015.1089243
- Wang YH, Morris-Natschke SL, Yang J, Niu HM, Long CL, Lee KH. 2014. Anticancer principles from medicinal piper (hú jiāo) plants. J Tradit Complement Med. 4:8–16.10.4103/2225-4110.124811
- Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. 2003. Kava lactones and the kava-kava controversy. Phytochemistry. 64:673–679.10.1016/S0031-9422(03)00381-9